CN113557236A - 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物 - Google Patents
一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物 Download PDFInfo
- Publication number
- CN113557236A CN113557236A CN202080018398.5A CN202080018398A CN113557236A CN 113557236 A CN113557236 A CN 113557236A CN 202080018398 A CN202080018398 A CN 202080018398A CN 113557236 A CN113557236 A CN 113557236A
- Authority
- CN
- China
- Prior art keywords
- compound
- substituted
- bifunctional
- unsubstituted
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物,所述调节剂具有如式I所示结构。双功能免疫调节剂包含同时阻断PD‑1/PD‑L1相互作用的苄苯醚类分子骨架和阻断TGF‑β信号通路的4‑(4‑吡唑)喹啉分子骨架,二者通过分子链片段相连接。因此,双功能免疫调节剂可同时阻断PD‑1/PD‑L1相互作用和TGF‑β信号通路。
Description
PCT国内申请,说明书已公开。
Claims (15)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910497925 | 2019-06-10 | ||
CN2019104979254 | 2019-06-10 | ||
PCT/CN2020/094580 WO2020248908A1 (zh) | 2019-06-10 | 2020-06-05 | 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113557236A true CN113557236A (zh) | 2021-10-26 |
CN113557236B CN113557236B (zh) | 2022-05-10 |
Family
ID=73780895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080018398.5A Active CN113557236B (zh) | 2019-06-10 | 2020-06-05 | 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113557236B (zh) |
WO (1) | WO2020248908A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113307779B (zh) * | 2021-05-25 | 2023-04-21 | 中国药科大学 | 杂环取代联苯类化合物、制备方法及用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1337950A (zh) * | 1999-01-08 | 2002-02-27 | 日本烟草产业株式会社 | 2-氧代喹啉化合物及其药物用途 |
US20100254899A1 (en) * | 2007-02-27 | 2010-10-07 | The United States Of America, As Represented By The Secretary, Dept Of Health And Human Services | Radiolabeled affibody molecules |
CN105705489A (zh) * | 2013-09-04 | 2016-06-22 | 百时美施贵宝公司 | 用作免疫调节剂的化合物 |
CN109305934A (zh) * | 2018-08-07 | 2019-02-05 | 成都海博锐药业有限公司 | 苯醚类衍生物及可药用盐、医药上的用途 |
CN109824621A (zh) * | 2019-03-28 | 2019-05-31 | 中国药科大学 | 噁二唑类和噻二唑类化合物及其制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1397364E (pt) * | 2001-05-24 | 2007-10-22 | Lilly Co Eli | Novos derivados de pirrole como agentes farmacêuticos |
UA80571C2 (en) * | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
US8871744B2 (en) * | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
CN108136001B (zh) * | 2015-04-03 | 2022-07-29 | 佐马技术有限公司 | 使用TGF-β抑制剂和PD-1抑制剂治疗癌症 |
US10745382B2 (en) * | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
-
2020
- 2020-06-05 CN CN202080018398.5A patent/CN113557236B/zh active Active
- 2020-06-05 WO PCT/CN2020/094580 patent/WO2020248908A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1337950A (zh) * | 1999-01-08 | 2002-02-27 | 日本烟草产业株式会社 | 2-氧代喹啉化合物及其药物用途 |
US20100254899A1 (en) * | 2007-02-27 | 2010-10-07 | The United States Of America, As Represented By The Secretary, Dept Of Health And Human Services | Radiolabeled affibody molecules |
CN105705489A (zh) * | 2013-09-04 | 2016-06-22 | 百时美施贵宝公司 | 用作免疫调节剂的化合物 |
CN109305934A (zh) * | 2018-08-07 | 2019-02-05 | 成都海博锐药业有限公司 | 苯醚类衍生物及可药用盐、医药上的用途 |
CN109824621A (zh) * | 2019-03-28 | 2019-05-31 | 中国药科大学 | 噁二唑类和噻二唑类化合物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2020248908A1 (zh) | 2020-12-17 |
CN113557236B (zh) | 2022-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7352587B2 (ja) | Krasg12c突然変異タンパク質阻害剤としてのピリドン-ピリミジン系誘導体 | |
JP7367908B2 (ja) | 標的タンパク質分解化合物、その抗腫瘍応用、その中間体および中間体の応用 | |
CN111484477B (zh) | 一种苯并吡啶酮杂环化合物及其用途 | |
JP7323603B2 (ja) | 三環式縮合フラン置換ピペリジンジオン系化合物 | |
CN108864057B (zh) | 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用 | |
JPH11269146A (ja) | 分化誘導剤 | |
JP6951406B2 (ja) | フラバグリン誘導体 | |
JP6836693B2 (ja) | A2a受容体アンタゴニストとしての縮合環誘導体 | |
CN112300153B (zh) | 一种杂环化合物、药物组合物和用途 | |
CN110092740B (zh) | 一种稠环化合物及其应用 | |
WO2021239133A1 (zh) | 作为axl抑制剂的嘧啶类化合物 | |
CN111393415A (zh) | 一种杂芳腈类化合物及其应用 | |
CN108689937B (zh) | 吲唑类化合物及其在制备ido抑制剂类药物上的用途 | |
CN115353508A (zh) | 5-吡啶-1h-吲唑类化合物、药物组合物和应用 | |
CN114981273A (zh) | 杂环酰胺类化合物、其可药用的盐及其制备方法和用途 | |
CN113557236B (zh) | 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物 | |
JP6606806B2 (ja) | 重水素化キナゾリノン化合物及び該化合物を含む薬物組成物 | |
CN109438347B (zh) | 一种氰基喹啉类ido1抑制剂、其制备方法及应用 | |
WO2006138180A1 (en) | Tubulin inhibitor and process for its preparation | |
WO2021240429A1 (en) | Benzofuran and benzopyran dihydroorotate dehydrogenase inhibitors | |
CN115677666A (zh) | 一种吲哚联嘧啶类化合物、其中间体、制备方法及其应用 | |
CN112876419A (zh) | 烯丙胺衍生物及其制备方法和用途 | |
JP7265681B2 (ja) | Acc1及びacc2阻害剤としての結晶形及びその製造方法並びに使用 | |
JP7198968B2 (ja) | チエノ[2,3-c]ピリダジン-4(1H)-オン系化合物の結晶形及びその製造方法並びに使用 | |
EP3498712B1 (en) | Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |